Skip to main content
Year archive

Verona Pharma plc — 2019 filings

All 107 regulatory filings released by Verona Pharma plc (VRNA) in 2019, sourced directly from the official regulator.

107 Filings
2019 Period
2019 filings (107)
Filing Released Lang
6-K
Foreign Filer Report
2019-11-29 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification
2019-11-28 English
Verona Pharma plc: Grant of Options to PDMR
Director's Dealing
2019-11-27 English
6-K
Foreign Filer Report
2019-11-22 English
6-K
Foreign Filer Report
2019-11-22 English
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
Director's Dealing
2019-11-18 English
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
Director's Dealing
2019-11-14 English
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
Regulatory Filings
2019-11-13 English
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
Regulatory Filings
2019-11-11 English
6-K
Foreign Filer Report
2019-11-05 English
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
Earnings Release 9M 2019
2019-11-05 English
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-10-29 English
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
Earnings Release Q4 2019
2019-10-17 English
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
Regulatory Filings
2019-10-15 English
6-K
Foreign Filer Report
2019-09-19 English
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
Regulatory Filings
2019-09-19 English
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
Regulatory Filings
2019-09-19 English
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
Regulatory Filings
2019-09-19 English
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
Regulatory Filings
2019-09-19 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification
2019-09-09 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification
2019-09-09 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification
2019-09-09 English
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Regulatory Filings
2019-09-03 English
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Regulatory Filings
2019-09-03 English
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Regulatory Filings
2019-09-03 English
6-K
Foreign Filer Report
2019-08-14 English
Verona Pharma plc: PDMR Dealing
Director's Dealing
2019-08-09 English
Verona Pharma plc: PDMR Dealing
Director's Dealing
2019-08-09 English
Verona Pharma plc: PDMR Dealing
Director's Dealing
2019-08-09 English
6-K
Foreign Filer Report
2019-08-08 English
6-K
Foreign Filer Report
2019-08-07 English
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
Interim / Quarterly Report H1 2019
2019-08-06 English
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
Interim / Quarterly Report H1 2019
2019-08-06 English
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
Interim / Quarterly Report H1 2019
2019-08-06 English
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
Earnings Release Q2 2019
2019-08-05 English
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
Earnings Release Q2 2019
2019-08-05 English
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
Earnings Release Q2 2019
2019-08-05 English
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-07-30 English
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-07-30 English
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-07-30 English
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
Regulatory Filings
2019-07-24 English
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
Regulatory Filings
2019-07-24 English
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
Regulatory Filings
2019-07-24 English
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
Regulatory Filings
2019-07-24 English
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
Board/Management Information
2019-06-25 English
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
Board/Management Information
2019-06-25 English
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
Board/Management Information
2019-06-25 English
6-K
Foreign Filer Report
2019-06-05 English
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
Regulatory Filings
2019-06-04 English
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
Regulatory Filings
2019-06-04 English
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
Regulatory Filings
2019-05-30 English
PDMR Dealing
Director's Dealing
2019-05-29 English
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
Earnings Release Q1 2019
2019-05-20 English
6-K
Foreign Filer Report
2019-05-14 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements
2019-05-07 English
6-K
Foreign Filer Report
2019-05-07 English
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
Regulatory Filings
2019-05-07 English
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
Earnings Release Q1 2019
2019-05-07 English
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
Regulatory Filings
2019-05-07 English
6-K
Foreign Filer Report
2019-05-03 English
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
Board/Management Information
2019-05-01 English
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-05-01 English
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
Investor Presentation
2019-04-25 English
6-K
Foreign Filer Report
2019-04-12 English
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Regulatory Filings
2019-04-09 English
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Regulatory Filings
2019-04-09 English
Grant of Options and RSUs and PDMR Dealings
Director's Dealing
2019-04-04 English
Grant of Options and RSUs and PDMR Dealings
Director's Dealing
2019-04-04 English
SC 13D
Major Shareholding Notification
2019-04-02 English
6-K
Foreign Filer Report
2019-03-26 English
6-K
Foreign Filer Report
2019-03-26 English
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Regulatory Filings
2019-03-26 English
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Regulatory Filings
2019-03-26 English
PDMR Dealing
Director's Dealing
2019-03-25 English
PDMR Dealing
Director's Dealing
2019-03-25 English
2018 Annual Report and Accounts and Notice of AGM 
Report Publication Announcement
2019-03-22 English
2018 Annual Report and Accounts and Notice of AGM 
Report Publication Announcement
2019-03-22 English
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
Board/Management Information
2019-03-21 English
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
Board/Management Information
2019-03-21 English
PDMR Dealing
Director's Dealing
2019-03-20 English
PDMR Dealing
Director's Dealing
2019-03-20 English
20-F
Annual Report FY 2018
2019-03-19 English
6-K
Foreign Filer Report
2019-03-12 English
PDMR Dealing
Director's Dealing
2019-03-11 English
PDMR Dealing
Director's Dealing
2019-03-11 English
PDMR Dealing
Director's Dealing
2019-03-07 English
PDMR Dealing
Director's Dealing
2019-03-07 English
PDMR Dealing
Director's Dealing
2019-03-05 English
PDMR Dealing
Director's Dealing
2019-03-05 English
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Regulatory Filings
2019-03-04 English
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Regulatory Filings
2019-03-04 English
6-K
Foreign Filer Report
2019-02-28 English
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
Investor Presentation
2019-02-28 English
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
Investor Presentation
2019-02-28 English
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
Report Publication Announcement FY 2018
2019-02-26 English
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
Earnings Release FY 2018
2019-02-26 English
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
Report Publication Announcement
2019-02-20 English
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
Report Publication Announcement
2019-02-20 English
SC 13G/A
Major Shareholding Notification
2019-02-12 English
SC 13G/A
Major Shareholding Notification
2019-02-11 English
Verona Pharma to Present at Upcoming Investor Conferences
Regulatory Filings
2019-02-04 English
Verona Pharma to Present at Upcoming Investor Conferences
Investor Presentation
2019-02-04 English
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Regulatory Filings
2019-01-14 English
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Regulatory Filings
2019-01-14 English
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
Regulatory Filings
2019-01-09 English
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
Regulatory Filings
2019-01-09 English
6-K
Foreign Filer Report
2019-01-04 English